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Abstract
Background: Nutritional deficits, cachexia, and sarcopenia are extremely common in esophageal cancer. The aim of
this article was to assess the effect of loss of skeletal muscle mass during neoadjuvant treatment on the prognosis
of esophageal cancer patients.
Methods: Esophageal cancer patients (N = 115) undergoing neoadjuvant therapy and surgery between 2010 and
2014 were identified from our surgery database and retrospectively analyzed. Computed tomography imaging of
the total cross-sectional muscle tissue measured at the third lumbar level defined the skeletal muscle index, which
defined sarcopenia (SMI < 52.4 cm2/m2 for men and < 38.5 cm2/m2 for women). Images were collected before and
after neoadjuvant treatments.
Results: Sarcopenia in preoperative imaging was prevalent in 92 patients (80%). Median overall survival was
900 days (interquartile range 334–1447) with no difference between sarcopenic (median = 900) and non-sarcopenic
(median = 914) groups (p = 0.872). Complication rates did not differ (26.1% vs 32.6%, p = 0.725). A 2.98% decrease in
skeletal muscle index during neoadjuvant treatment correlated with poor 2-year survival (log-rank p = 0.04).
Conclusion: Loss of skeletal muscle tissue during neoadjuvant treatment correlates with worse overall survival.
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Background
Esophageal cancer (EC) is intimately related to weight
changes and poor nutritional status, since the most com-
mon symptoms of EC are dysphagia and weight loss [1].
In locally advanced EC, baseline nutritional status has
been linked to survival after definitive chemoradiother-
apy [2]. Preoperative weight loss has also been linked to
worse outcomes [3]. A high body mass index (BMI) has
not been found to have a significant effect on survival in
EC [4, 5].
In the recent years, there has been an increasing
amount of studies on frailty and especially sarcopenia as
prognostic factors in cancers. Sarcopenia is defined as
the progressive loss of muscle related to aging or disease
[6]. Sarcopenia has been associated with worse outcomes
in many types of cancers such as hepatocellular carcin-
oma, colorectal cancer, and small cell lung cancer [7–9].
For esophageal and gastroesophageal junction cancers,
there are conflicting reports. Worse long-term outcomes
have been reported in resected esophageal or gastro-
esophageal junctional cancers [10–12]. Sarcopenia has
been linked to increased pulmonary and other complica-
tion rates [13, 14]. Decreased skeletal muscle area during
neoadjuvant therapy has also been associated with
poorer outcomes and risk of positive clinical resection
margin [15, 16]. There are also reports of sarcopenia not
being an independent prognostic risk factor for mortal-
ity, morbidity, or poor outcomes in EC after neoadjuvant
chemoradiotherapy or chemotherapy [14, 17–19]. One
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study found a significant correlation with lean psoas
mass and survival in patients not undergoing neoadju-
vant treatment, but no such effect on patients receiving
neoadjuvant treatment [20].
The aim of this trial was to assess the effect of sarco-
penia and loss of skeletal muscle index during neoadju-
vant treatments in patients undergoing esophagectomy
for EC. The primary end-point is overall survival, and
secondary end points are recurrence-free survival and
complication rates.
Methods
Patients
Patients who underwent surgical resection and neoadju-
vant therapy for EC between 2010 and 2014 were identi-
fied in retrospect from our surgery database using type of
surgery and diagnosis of esophageal or junctional cancer
as identifiers (N = 118). Patients who had no eligible
imaging for analysis of the skeletal muscle index were
excluded (N = 3), leaving 115 patients. Collected data
included patient characteristics, weight, and weight-loss
data before and during the treatment and follow up, pri-
mary tumor characteristics and staging, specifics of neoad-
juvant, endoscopic, surgical and adjuvant treatments,
post-operative and long-term complications, and overall
survival. Weight loss here is defined as unintentional devi-
ation from healthy weight (weight 6 months before diag-
nosis). Complications were collected as recommended by
an international consensus statement [21]. 30- and 90-day
overall survival rates and 2-year overall survival and
recurrence-free survival rates were also collected.
CT (computed tomography) scans were collected from
time of initial staging, post-neodjuvant, 6-, and 18-month
follow-up visits. CT scans were excluded if there was
impaired visibility at third lumbar vertebra or over
1 month of time interval between the CT scan and
associated event (start of neoadjuvant therapy, operation,
6-month follow-up visit, or 18-month follow-up visit).
Preoperative staging
All patients underwent gastroscopies with biopsies that
confirmed the diagnosis of EC. All patients underwent
CT scans of the thorax, abdomen, and pelvis and a rou-
tine total body PET-CT scan. Endoscopic ultrasound was
done unless prevented by tumor obstruction or stent
insertion and assessed the invasion depth of the tumor
and identified regional enlarged lymph nodes. PET/CT
scans were routinely repeated after neoadjuvant treat-
ments for preoperative planning and to assess the radio-
logic response of the tumor.
Neoadjuvant treatment protocols
Treatment strategies were discussed and decided together
with oncologists. Patients with nodal disease spread (cN+)
or transmural tumor invasion (cT ≥ 3) underwent neoad-
juvant treatment, unless contraindicated. Neoadjuvant
therapy was epirubicin–oxaliplatin–capecitabine neoadju-
vant chemotherapy as per MAGIC (Medical Research
Council Adjuvant Gastric Infusional Chemotherapy)
protocol for esophageal adenocarcinoma [22]. Squamous
cell carcinoma was treated with neoadjuvant chemoradio-
therapy consisting of 2 cycles of platin- and 5-
fluorouracil-based therapy over 5–6 weeks. Chemosensiti-
zation was followed by a 45 Gy total dose of radiation to
the tumor and regional nodes, in 1.8 Gy daily fraction.
Preoperative endoscopic procedures
Endoscopic mucosal resection (EMR) with or without
radiofrequency ablation (RFA) was discussed as an op-
tion for patients with mucosal tumors or high-grade dys-
plasia. The initial decision whether to proceed with
endoscopic treatments or to do an esophagectomy was a
shared decision between the surgeon and the patient. If
endoscopic mucosal resection showed submucosal
spread or there was cancer recurrence, treatment pro-
ceeded to esophagectomy. One patient included in this
Fig. 1 An example of SMI delineating. a Shows a male patient
without sarcopenia (SMI = 57.6 cm2/m2), whereas b shows the same
patient with sarcopenia (SMI = 47.9 cm2/m2) at follow-up
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study had a prior EMR. Patients with obstructing tumor
growth and marked dysphagia preventing the ingestion
of solid foods were treated with insertion of a self-
expandable metallic stent (SEMS, N = 35) or a percutan-
eous endoscopic gastrostomy (PEG, N = 4) tube.
Surgical treatment and follow-up
Surgical techniques included minimally invasive esopha-
gectomy, hybrid minimally invasive esophagectomy with
either laparoscopy or video-assisted thoracoscopic
surgery, Ivor-Lewis esophagectomy, 3-part esophagec-
tomy, and transhiatal esophagectomy. These techniques
are described elsewhere [23]. Post-operative stage of the
tumor was reported according to eighth edition AJCC/
IAUC staging [24]. Amount of positive lymph nodes and
total lymph node count was recorded.
Patients were followed until death or January 2017,
yielding a follow-up period of at least 24 months. Patients
were met at an outpatient clinic 1 month after surgery to
assess the recovery from surgery. Gastroscopies were done
every 6 months for 2 years after surgery and annually for
up to 5 years. CT scans were taken 6 months after surgery,
18 months after surgery, and annually up to 5 years.
All the treatments discussed here are standard
approaches in our institution.
Measurement of muscle parameters and sarcopenia
definition
Scans were coded in order to blind the researcher from
outcome. Images were imported to Osirix® Version 3.3
Table 1 Baseline characteristics of the study patient population
Overall Pre-operative sarcopenia p
No Yes
Number of patients
(%)
115 23 92
Sex (%)
Female 29 (25.2) 9 (39.1) 20 (21.7) 0.147
Male 86 (74.8) 14 (60.9) 72 (78.3)
ECOG (%)
0 40 (35.1) 11 (47.8) 29 (31.9) 0.140
1 69 (60.5) 10 (43.5) 59 (64.8)
2 5 (4.4) 2 (8.7) 3 (3.3)
Smoking status (%)
Current smoker 32 (27.8) 11 (47.8) 21 (22.8) 0.018
Ex-smoker 40 (34.8) 3 (13.0) 37 (40.2)
Non-smoker 43 (37.4) 9 (39.1) 34 (37.0)
T stage (%)
1 2 (1.8) 0 (0.0) 2 (2.2) 0.894
2 10 (8.9) 2 (8.7) 8 (9.0)
3 86 (76.8) 17 (73.9) 69 (77.5)
4 14 (12.5) 4 (17.4) 10 (11.2)
N stage (%)
0 33 (29.5) 6 (26.1) 27 (30.3) 0.258
1 74 (66.1) 15 (65.2) 59 (66.3)
2 4 (3.6) 1 (4.3) 3 (3.4)
3 1 (0.9) 1 (4.3) 0 (0.0)
Cancer type (%)
Adenocarcinoma 88 (76.5) 21 (91.3) 67 (72.8) 0.061
SCC* 27 (23.5) 2 (8.7) 25 (27.2)
Pathological grade** (%)
1 9 (16.1) 2 (28.6) 7 (14.3) 0.723
2 22 (39.3) 3 (42.9) 19 (38.8)
3 25 (44.7) 2 (28.6) 23 (46.9)
Tumor location (%)
Lower third 95 (82.6) 20 (87.0) 75 (81.5) 0.646
Middle third 17 (14.8) 3 (13.0) 14 (15.2)
Upper third 3 (2.6) 0 (0.0) 3 (3.3)
Neoadjuvant treatment (%)
Chemoradiation 28 (24.3) 2 (8.7) 26 (28.3) 0.051
Chemotherapy 87 (75.7) 21 (91.3) 66 (71.7)
Operation type (%)
MIE† 78 (67.8) 18 (78.3) 60 (65.2) 0.464
Thoracotomy 26 (22.6) 2 (8.7) 24 (26.1)
Hybrid-laparoscopy 5 (4.3) 1 (4.3) 4 (4.3)
Hybrid-VATS‡ 3 (2.6) 1 (4.3) 2 (2.2)
Transhiatal 3 (2.6) 1 (4.3) 2 (2.2)
Preop. endo. treatment (%)
Any 40 (34.8) 4 (17.4) 36 (39.1) 0.087
Table 1 Baseline characteristics of the study patient population
(Continued)
Overall Pre-operative sarcopenia p
No Yes
Stent 35 (30.4) 3 (13.0) 32 (34.8) 0.076
PEG§ 4 (3.5) 1 (4.3) 3 (3.3) 1.000
EMR¶ 1 (0.9) 1 (4.3) 0 (0.0) 0.451
Age, years (mean
[SD])
63 [9] 59 [8] 64 [9] 0.015
Height, cm (median
[IQR])
174 [166,179] 171 [160,174] 175 [167,180] 0.009
Preop. weight, kg
(mean [SD])
74 [16] 82 [18] 73 [15] 0.017
Weight loss, kg
(median [IQR])
7 [0, 13] 6 [0, 12] 8 [2, 12] 0.509
FEV1% (mean [SD]) 90 [18] 90 [21] 91 [18] 0.914
Creatinine, umol/l
(mean [SD])
71 [19] 72 [18] 71 [20] 0.810
CCI (median [IQR]) 5 [4, 6] 5 [4, 6] 5 [5, 6] 0.098
*Squamous cell carcinoma
**Grade not reported on all pathological reports
†Minimally invasive esophagectomy
‡Video-assisted thoracoscopic surgery
§Percutaneous endoscopic gastrostomy
¶Endoscopic mucosal resection
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Fig. 2 The evolution of mean body weight, body mass index, and skeletal muscle index during follow-up in the whole study population (n = 115)
Table 2 Analysis of complication rates by preoperative sarcopenia
Preoperative
Sarcopenia
Level No Yes p
(N = 23) (N = 92)
30-day mortality (%) 0 (0.0) 3 (3.3) 0.884
90-day mortality (%) 1 (4.3) 6 (6.5) 1.000
Any complication (%) 17 (73.9) 62 (67.4) 0.725
Clavien-Dindo score (%) 0 6 (26.1) 30 (32.6) 0.886
1 0 (0.0) 3 (3.3)
2 4 (17.4) 10 (10.9)
3a 3 (13.0) 13 (14.1)
3b 7 (30.4) 20 (21.7)
4a 2 (8.7) 11 (12.0)
4b 0 (0.0) 2 (2.2)
5 1 (4.3) 3 (3.3)
Chyle leak (%) 1 (4.3) 8 (8.7) 0.795
Anastomotic leak (%) 2 (8.7 13 (14.1) 0.729
Conduit necrosis (%) 1 (4.3) 2 (2.2) 1.000
Recurrent nerve palsy (%) 1 (4.3) 7 (7.6) 0.927
Intraoperative Complications† (%) 3 (13.0) 9 (9.8) 0.939
Pulmonary complications‡ (%) 6 (26.1) 26 (28.3) 1.000
Reoperation rate (%) 2 (8.7) 8 (8.7) 1.000
Operative bleeding, ml (median [IQR]) 200 [150, 400] 400 [150, 700] 0.091
ICU stay, days (median [IQR]) 3 [1, 5] 2 [1, 4] 0.535
Tracheostomy rate (%) 1 (4.3) 8 (8.7) 0.795
†Intraoperative vessel, conduit or airway injury or conversion to open esophagectomy
‡Contains ARDS (acute respiratory distress syndrome), pneumonia, atelectasis requiring intervention, pleural effusion or pneumothorax requiring intervention,
pulmonary embolism, and acute aspiration
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(32-bit Pixmeo, Sarl, Switzerland). We selected a single
image on the level of L3, with both transverse processes
and delineated abdominal muscles by use of a semi-
automated selection of region of interest. Psoas,
quadratus lumborum, paraspinal, transverse abdominal,
external oblique, internal oblique, and rectus abdominis
muscles were included. The Hounsfield unit threshold
range for skeletal muscle was − 29 to + 150. The images
were manually corrected, if needed, by the propulsion
and brush tools in Osirix©. The cross-sectional total
muscle area at the level of L3 (cm2) was divided by the
square of height (m2), which produced the skeletal
muscle index (SMI). This method is suggested as
the preferred method of measuring the muscle mass
of cancer patients [25]. SMI limit for sarcopenia was
< 52.4 cm2/m2 for men and < 38.5 cm2/m2 for
women, based on a previous study by Prado et al. [26] For
the survival and complication analyses, the preoperative
SMI values were used, unless stated otherwise.
The process of delineating the abdominal muscle mass
is shown in Fig. 1.
Statistical analysis
All statistical analysis was done with R Project. (R Core
Team, 2016). R: A language and environment for statis-
tical computing. R Foundation for Statistical Computing,
Vienna, Austria. URL: https://www.R-project.org/).
Continuous parameters were tested for normality using
Shapiro-Wilk’s test and deemed normally distributed if
p > 0.05. Normal continuous data is presented as mean
and standard deviation (SD) whereas non-normal data is
described with median and interquartile range (IQR). For
comparing normal scalar variables between two groups,
independent samples Student’s t test was used and for
non-normal variables Mann-Whitney U test was used.
The 2-tailed χ2 test served for categorical variables.
Kaplan-Meier survival analysis and log-rank test
demonstrated the possible difference of survival between
groups.
Results
Baseline characteristics of the study population are dis-
played in Table 1. Included patients numbered 115, of
which sarcopenia was found in 92 (80%). Median overall
survival was 900 days (interquartile range 334–1447).
Patients with and without preoperative sarcopenia are
compared in Table 1. The sarcopenic patients were
statistically significantly older, taller, weighed less, and
had smaller prevalence of current smokers.
The progression of mean weight- and body composition-
related parameters during neoadjuvant treatments and
follow-up is displayed in Fig. 2. Ninety-one (79.1%) patients
had sarcopenia before neoadjuvant treatments, 92 (80%)
were sarcopenic before esophagectomy, 82 of 99 (82.8%)
a b
Fig. 3 a Shows the 2-year Kaplan-Meier survival curve for the sarcopenic and non-sarcopenic groups and b shows the 2-year recurrence-free survival
curves for these groups
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were sarcopenic 6 months post-operatively, and 67 of 78
(85.9%) 18 months post-operatively.
Table 2 shows the relevant complication rates and
Clavien-Dindo scores of patients. The amount of intra-
operative bleeding and length of initial intensive care
unit stay are also displayed. There was no statistically
significant difference between the sarcopenic or non-
sarcopenic groups in any complication groups. An
additional table shows a more exhaustive table of
complication rates [see Additional file 1].
There was no statistical difference in 2-year overall sur-
vival or recurrence-free survival between the preoperative
sarcopenic and non-sarcopenic groups (p = 0.74 and p =
0.64, respectively). The Kaplan-Meier curves are shown in
Fig. 3a, b. Neither preneoadjuvant SMI nor preoperative
SMI had an effect on OS (p = 0.6023 and p = 0.3843) or
RFS (p = 0.3241 and p = 0.9273).
Patients were divided into groups based on the change
between preneoadjuvant measurement and preoperative
measurement of SMI. Median percentual change of SMI
(− 2.98%) was used as the cut-off value, as has been done
in a previous study [15]. The baseline characteristics are
displayed in Table 3. The group with more muscle loss
had more preoperative stents inserted (p = 0.037). SMI
change below the median correlated with 2-year overall
survival (p = 0.022) but not 2-year RFS (p = 0.11), as
shown in Fig. 4a–b. The change of SMI during neo-
adjuvant treatments was significantly different be-
tween 2-year survivors and non-survivors with mean
changes of − 0.69 and − 6.20%, respectively (p = 0.01259).
Table 3 Characteristics by SMI change groups
SMI change p
< − 2.98% > − 2.98%
Number of patients (%) 57 58
Sex (%)
Female 19 (33.3) 10 (17.2) 0.076
Male 38 (66.7) 48 (82.8)
ECOG (%)
0 15 (26.3) 25 (43.9) 0.108
1 40 (70.2) 29 (50.9)
2 2 (3.5) 3 (5.3)
Smoking status (%)
Current smoker 20 (35.1) 12 (20.7) 0.086
Ex-smoker 21 (36.8) 19 (32.8)
Non-smoker 16 (28.1) 27 (46.6)
T stage
1 2 (3.8) 0 (0.0) 0.549
2 5 (9.3) 5 (8.6)
3 42 (77.8) 44 (75.9)
4 5 (9.3) 9 (15.5)
N stage
0 14 (25.9) 19 (32.8) 0.445
1 38 (70.4) 36 (62.1)
2 1 (1.9) 3 (5.2)
3 1 (1.9) 0 (0.0)
Cancer type (%)
Adenocarcinoma 40 (70.2) 48 (82.8) 0.111
SCC* 17 (29.8) 10 (17.2)
Pathological grade**
1 3 (13.0) 6 (18.2) 0.790
2 9 (39.1) 13 (39.4)
3 12 (47.9) 14 (42.4)
Tumor location (%)
Lower third 45 (78.9) 50 (86.2) 0.357
Middle third 11 (19.3) 6 (10.3)
Upper third 1 (1.8) 2 (3.4)
Neoadjuvant treatment (%)
Chemoradiation 19 (33.3) 11 (19.0) 0.079
Chemotherapy 38 (66.7) 47 (81.0)
Operation type (%)
MIE† 39 (68.4) 39 (67.2) 0.931
Thoracotomy 13 (22.8) 13 (22.4)
Hybrid-laparoscopy 2 (3.5) 3 (5.2)
Hybrid-VATS‡ 2 (3.5) 1 (1.7)
Transhiatal 1 (1.8) 2 (3.4)
Table 3 Characteristics by SMI change groups (Continued)
SMI change p
< − 2.98% > − 2.98%
Preop. endo. treatment (%)
Any 26 (45.6) 14 (24.1) 0.026
Stent 23 (40.4) 12 (20.7) 0.037
PEG§ 2 (3.5) 2 (3.4) 1.000
EMR¶ 1 (1.8) 0 (0.0) 0.993
Age, years (mean [SD]) 63 [9] 63 [9] 0.817
Height, cm (median [IQR]) 173 [164,179] 174 [168,179] 0.350
Preop. weight, kg (mean [SD]) 74 [17] 75 [16] 0.840
Weight loss, kg (median [IQR]) 10 [0, 15] 6 [2, 10] 0.131
FEV1% (mean [SD]) 89 [21] 92 [16] 0.527
Creatinine, umol/l (mean [SD]) 70 [22] 72 [16] 0.484
CCI (median [IQR]) 5 [5, 6] 5 [4, 6] 0.397
*Squamous cell carcinoma
**Grade not reported on all pathological reports
†Minimally invasive esophagectomy
‡Video-assisted thoracoscopic surgery
§Percutaneous endoscopic gastrostomy
¶Endoscopic mucosal resection
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Finally, a multivariate Cox regression analysis was
done using the backwards elimination method with a p
value limit of 0.2. The model constructed is shown in
Table 4. The model showed that the patients who had
percentual SMI change over the median (− 2.98%) had
better survival than those whose SMI had decreased
more (p = 0.049; HR − 0.609; HR 95% CI 0.297–0.997).
No other covariates reached significance (N stage, T
stage, or CCI). There was 11.75 events per variable (47
events, 4 variables), which is over the suggested limit of
10 (Table 4) [27].
Discussion
Our findings suggest that loss of skeletal muscle mass dur-
ing neoadjuvant treatment of EC is a marker of poor prog-
nosis. Sarcopenia itself was not correlated with poorer
oncological outcomes; however, its prevalence is high in
this population and increases post-esophagectomy.
The amount of skeletal muscle lost during neoadjuvant
treatment seems to predict a poorer prognosis. A
median cut-off of − 2.98% produced significantly differ-
ent 2-year overall survival rates as seen in Fig. 4a. To the
authors’ best knowledge, this finding has not been previ-
ously reported in published literature, although similar
findings have been reported in squamous cell carcinoma
patients [15]. A previous study failed to show this correl-
ation, but concluded that the amount of skeletal muscle
lost during neoadjuvant therapy differed significantly
between survivors and non-survivors, which was
confirmed by our study [16]. Skeletal muscle wasting
post-operatively has been associated with worse out-
comes in thoracic esophageal cancer [28].
a b
Fig. 4 Kaplan-Meier survival analyses of the patients divided into groups by skeletal muscle index change by cut-off of − 5%. a Shows the 2-year
overall survival rates between the groups and b shows the 2-year recurrence free survival
Table 4 Multivariate Cox regression analysis of the covariates affecting OS
HR 95% CI p
ΔSMI%* during neoadj. (>median vs. <median) -0.609 0.297–0.997 0.049
N stage (per level) 0.486 0.940–2.801 0.082
T stage (per level) 0.496 0.993–2.892 0.086
CCI** (per level) 0.175 0.973–1.459 0.091
*The percentual change in skeletal muscle index during neoadjuvant treatments
**Charlson comorbidity index
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The progression of sarcopenia is not stopped by resec-
tion of the tumor according to our data as shown in
Fig. 2. The prevalence of sarcopenia increases with time
in follow-up. Similar findings have been reported in the
literature [14]. Esophagectomy seems to affect the body
composition of many patients. An interventional ran-
domized study did not see statistically significant change
in the weight of patients’ post-esophagectomy at 7 days,
regardless of the method of nutritional support [29]. A
previous study has shown that malnutrition and weight
loss is common even years after EC surgery [30].
Whether this change in body mass post-esophagectomy
contributes to the morbidity or mortality of operatively
treated EC patients is unknown.
Sarcopenia was not correlated with worse overall
survival or recurrence-free survival in our study. This
finding contradicts many previous studies and is sup-
ported by some previous studies [10–18]. Complication
rates in any of the complication subgroups did not differ
significantly between sarcopenic and non-sarcopenic
groups. There was a statistically non-significant increase
in operative bleeding with sarcopenic patients.
Our study has a number of limitations. The study is
retrospective in nature without randomization. This
increases the risk for systemic errors and selection bias.
The number of patients included in the study is of
adequate size taking into account the incidence of this
disease, but statistical power is of concern especially in
regard to complication rates and specific complication
where the number of events is low or non-existent.
Conclusions
In conclusion, our study found an interesting correlation
between the loss of skeletal muscle during neoadjuvant
treatment and worse oncological outcomes in surgically
treated EC patients. This finding should guide further
investigation into the interventions for nutritional support
in esophageal cancer and into the significance of indirect
measurements of body composition in the prognosis of
EC patients.
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Additional file 1: Complication rate analysis by preoperative sarcopenia.
(XLSX 34 kb)
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